Mytolac (Lanreotide Acetate)

Lanreotide acetate mimics natural somatostatin and binds to somatostatin receptors SSTR2 and SSTR5 on target cells. This binding blocks intracellular signaling pathways that normally stimulate the release of growth hormone, ACTH, insulin‑like growth factor‑1, and various gastrointestinal hormones, thereby reducing pathological hormone levels.

The dosing regimen for Mytolac is individualized and must be determined by a qualified prescriber based on the patient’s specific condition, disease severity, and response to therapy. Clinicians adjust the dose and injection interval according to clinical guidelines and patient monitoring.

Safety data for lanreotide acetate in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To request Mytolac, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Both Mytolac (lanreotide) and octreotide belong to the somatostatin analog class and share similar mechanisms of receptor binding. Lanreotide typically offers a longer dosing interval, allowing monthly or quarterly injections, whereas octreotide often requires more frequent dosing. Choice of therapy depends on patient preference, disease characteristics, and physician assessment.

Mytolac should be stored refrigerated at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 minutes before use.

Mytolac is given as a subcutaneous injection, usually into the abdomen or thigh. The injection is performed by a trained healthcare professional or, after proper instruction, by the patient or caregiver. The injection site should be rotated to minimize local irritation.

Serious adverse events include gallbladder disease (such as cholelithiasis), acute pancreatitis, severe hyperglycemia or diabetic ketoacidosis, allergic reactions including anaphylaxis, and cardiovascular complications. Patients should be monitored regularly for these conditions, and any concerning symptoms should prompt immediate medical evaluation.

Mytolac is contraindicated in patients with known hypersensitivity to lanreotide acetate or any excipients in the formulation. Caution is advised for individuals with severe uncontrolled diabetes, active gallbladder disease, pancreatitis, or significant cardiac disorders. The drug should also be avoided in patients for whom a somatostatin analog is medically inappropriate.